Hot Insurance Stocks To Own Right Now

9 New 2018 Tax Numbers to Know

Federal Judge May Keep ACA Subsidy Money Flowing

Trump Tax Cuts and Tax-Free Retirement Planning

The people who sell insurance products and securities through financial institutions were more productive this past August than they were in August 2016, according Stathis Partners.

Stathis Partners looked at August financial institution sales production figures with help from LPL Financial, for a monthly report distributed by the Bank Insurance & Securities Association 

Stathis Partners analysts found that bank financial consultant revenue from one-time sales transactions fell to $about 16,000in August, from about $19,000 in the comparable month in 2016.

But, thanks to strong sales in the past of products that generate recurring revenue, recurrent revenue averaged about $22,000 per financial consultant, up from about $14,600 per consultant in August 2016.

Representatives for platform programs were also more productive. They averaged about $1,300 in sales in August, up from about $1,000 in August 2016. 

Hot Insurance Stocks To Own Right Now: Inphi Corporation(IPHI)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Inphi (IPHI) provides high-speed analog and mixed signal semiconductor solutions for the communications, datacenter and computing markets. This stock closed up 4.7% at $13.25 in Monday’s trading session.

    Monday’s Volume: 838,000

    Three-Month Average Volume: 202,080

    Volume % Change: 378%

    From a technical perspective, IPHI jumped higher here right above some near-term support at $12.44 with heavy upside volume. This stock has been uptrending strong for the last five months, with shares soaring higher from its low of $8.62 to its intraday high of $13.85. During that uptrend, shares of IPHI have been consistently making higher lows and higher highs, which is bullish technical price action. That move briefly pushed shares of IPHI into breakout territory, since the stock flirted with some near-term overhead resistance at $13.50.

    Traders should now look for long-biased trades in IPHI as long as it’s trending above some near-term support at $12.44 and then once it sustains a move or close above its new 52-week high at $13.85 with volume that hits near or above 202,080 shares. If we get that move soon, then IPHI will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are its next major overhead resistance levels at $14.79 to $16.94, or possibly even $18.

  • [By Lisa Levin]

    Technology shares rose by 1.9 percent in the US market on Friday. Top gainers in the sector included Fabrinet (NYSE: FN), and Inphi Corporation (NYSE: IPHI).

Hot Insurance Stocks To Own Right Now: J.M. Smucker Company (The)(SJM)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    The Pillsbury Doughboy is the mascot of the Pillsbury Company, which is owned by General Mills (NYSE: GIS) and J.M. Smucker (NYSE: SJM). The Doughboy was created by Pillsburys advertising agency almost 50 years ago. Pikachu are characters owned by The Pokemon Company International and appear in card games, video games, TV shows, movies and comic books. Founded in 1998, the Japanese company has achieved total games sales of almost 280 million. SpongeBob SquarePants was created for Nickelodeon, which is owned by Viacom (NASDAQ: VIA). The show premiered in 1999 and has spawned movies, video games and theme park rides. Ronald McDonald is a c

  • [By Teresa Rivas]

    J.M. Smucker(SJM) is falling Monday, after Morgan Stanley’sMatthew Grainger and his team cut their rating on the stock, citing pricing pressures from Wal-Mart (WMT) and growing competition from private-labels.

    Getty Images

    Grainger slash Smucker to Underweight from Equal Weight, and shaved $6 off his price target, to $126. He also cites what he calls “sustained” challenges in both its coffee and pet food business, as well as“below-average strategic optionality.”

    At the same time, he also upgraded Pinnacle Foods (PF) to Overweight from Equal Weight, and raised his price target to $63 from $58, on its double-digit earnings growth and what he sees as superior execution.

    Nonetheless, he sees many of the packaged food companies in his coverage, from Smucker to Pinnacle, as subject to pressure from Wal-Mart and off-brand rivals. From the note:

    Walmart comprises ~22% of sales across our coverage, a figure that has increased in recent years even as the retailers total grocery sales have grown at an even faster 4% CAGR. With Food margins expected to expand meaningfully, we believe this only enhances Walmart’s negotiating leverage going forward. SJM, Dean Foods (DF), and General Mills (GIS) are most at risk in the current environment, in our view.

    Recent scanner data points to a positive inflection in private label trends (share up ~30 bps L12W) across a range of center-store categories, a dynamic we believe could intensify in an increasingly competitive retail grocery landscape. Our analysis of recent trends points to the most meaningful underperformance vs. private label at GIS, SJM, ConAgra (CAG), and Campbell Soup (CPB), while only PF has outperformed in recent weeks.

    Smucker is down 1.1% to $127.95 this morning, while Pinnacle is up 0.8% to %48.47.

Hot Insurance Stocks To Own Right Now: Cellectis S.A.(CLLS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cellectis SA (ADR) (NASDAQ: CLLS) shares dropped 20 percent to $25.70 after announcing FDA clinical hold of UCART123 studies.

    Shares of Opiant Pharmaceuticals Inc (NASDAQ: OPNT) were down 10 percent to $35.20. Opiant Pharma named David O'Toole as CFO.

  • [By Jim Robertson]

    Yesterday, small cap clinical-stage biopharmaceutical stock Cellectis SA (NASDAQ: CLLS) reported that they had received notice fromFDA that a clinical hold was placed on both UCART123 ongoing Phase 1 studies -in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The clinical hold was initiated after Cellectis reported one fatality in the BPDCN clinical trial (ABC study) with the Company now working closelywith the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123. The FDA has a detailed page about clinical holds which mentions:

Leave a Reply

Your email address will not be published. Required fields are marked *